摘要
目的研究不同剂量的化疗药尼莫司汀（ACNU）局部用于SD大鼠正常脑组织后，对大鼠改良神经功能损伤评分（mNSS）的影响。方法SD大鼠45只按随机数字表法分成A、B、C、D、E5组（E组5只，余每组10只），施以麻醉后常规开颅，暴露左侧大脑半球，剪开硬脑膜、蛛网膜，用2mm×2mm×2mm的明胶海绵分别蘸取0．4mL ACNU溶液（A-E组剂量分别为2mg／kg、lmg／kg、0．5mg／kg、0．25mg／kg、0mg／kg）敷于大鼠左侧大脑半球表面，手术缝合伤口。术后6h、1d、3d、7d、10d、14d观察大鼠mNSS的变化。结果不同剂量组大鼠之间mNSS不同，差异有统计学意义（P〈0．05）；各组大鼠正常脑组织局部应用ACNU后不同时间mNSS的变化趋势不同，差异有统计学意义（P〈0．05）；其中D、E组变化较为稳定；在相同时间点上，A、B、C组大鼠mNSS评分高于D、E组，差异有统计学意义（P〈0．05）；各组大鼠mNSS评分随着时间的延长先增加后减少。结论0．25mg／kg及以下剂量的ACNU溶液可作为接触大鼠正常脑组织的安全剂量。
Objective To study the effect of ACNU, a kind of antineoplastic, on scores of modified neurological severity scale （mNSS） when it with different concentrations contacted to the local cerebral tissues of rats. Methods Forty-five SD rats were randomly divided into 5 groups, including Group A, B, C and D （n=10） and Group E （n=5）. After being anesthetized, the parietal of the rats was opened to exposure the left cerebral hemisphere, and then the gelfoam （specification as 2 mm ×2 mm ×2 mm） dipped with the different doses （2, 1, 0.5, 0.25 and 0 mg/kg） of ACNU solution were respectively applied on the surface of the rat hemisphere in Group A, B, C and D and Group E. The wound was then surgically closed. The mNSS scores in every group were respectively evaluated at 6 h, and 1, 3, 7, 10 and 14 d after the administration of ACNU. Results The mNSS scores showed significant difference between each 2 groups （P〈0.05）; the trends of mNSS scores were also obviously different at different times after the administration ofACNU （P〈0.05）; the changes were much stable in Group D and E; at the same time point, the mNSS scores in Group A, B and C were significantly higher than those in Group D and E （P〈0.05）; the mNSS scores were increased at first and then decreased following the prolongation of administration time. Conclusion The 0.25 mg/kg of ACNU or lower doses of that could be considered as safe doses for applying to the normal cerebral tissue of rats.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2012年第7期672-675,共4页
Chinese Journal of Neuromedicine
基金
广东省科技计划项目（20118031800233）
国家临床重点专科建设项目
